Modulight Corporation has received commitments covering several customers utilizing its Pay-Per-Treatment model (PPT) across various therapeutic indications.
 
The Pay-Per-Treatment model typically allows customers to pay per use without upfront commitments. However, under the agreements announced today, customers have committed to minimum treatment volumes, which differs from Modulight’s standard PPT offering. Total proceeds may be higher if the number of treated patients exceeds the estimates in the agreements. Revenue recognition will occur in the usual manner following the delivery of service. 
 
The total minimum value of these customer commitments for PPT in clinical trials and commercial pilots exceeds 1.5 million dollars over the next two years. These contracts cover approximately 20 sites and involve customers including pharmaceutical and managed care companies, as well as leading hospitals and clinics in oncology and ophthalmology. Customers are utilizing both of Modulight’s clinical product platforms, ML7710 and ML6710i, through Modulight Cloud service (cloud.modulight.com) under the PPT model. 
 
“These contracts mark a significant milestone in the commercial validation of our Pay-Per-Treatment (PPT) business model and in customers’ willingness to adopt it”, says Seppo Orsila, Founder & CEO. “We are particularly excited to see leading healthcare and pharmaceutical companies adopting our solution, as well as the diversity among our customers. Their confidence and consistently positive feedback are clearly reflected in these agreements. We believe this step will help us reach more patients and scale our technology across a large number of sites. Customers have already treated patients on a small scale, and we expect to add more sites and see an increase in customer usage in 2025.”